The hazard ratio for PFS events compared with placebo was 069 ( 80 % CI 049-097 ; p = 0164 ) for rilotumumab 15 mg/kg , 053 ( 80 % CI 038-073 ; p = 0009 ) for rilotumumab 75 mg/kg , and 060 ( 80 % CI 045-079 ; p = 0016 ) for combined rilotumumab .